RELMADA THERAPEUTICS INC (RLMD)
Health Care · Biotechnology · NASDAQ
Relmada Therapeutics is a clinical-stage biotechnology company developing a pipeline of differentiated therapies, led by a sustained-release intravesical chemotherapy for bladder cancer and a neurosteroid for rare CNS disorders.
What RELMADA THERAPEUTICS INC does
Relmada Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies for oncology and central nervous system disorders. The company's lead product candidate is NDV-01, a sustained-release intravesical chemotherapy formulation for non-muscle-invasive bladder cancer (NMIBC). It is also developing sepranolone, a neurosteroid being investigated for conditions such as Prader-Willi syndrome and Tourette syndrome.
Recent developments
The company appointed Bipin Dalmia as Chief Business Officer to lead commercial planning and strategy. It is currently preparing for IND filings for both NDV-01 and sepranolone by year-end 2026, with Phase 3 registrational programs for NDV-01 expected to follow IND clearance.
From RELMADA THERAPEUTICS INC's filing of 2026-08-06.
Themes: oncology / bladder cancer, neurology / CNS disorders, drug delivery systems, neurosteroids
Fundamentals
- Price$3.17 as of 2026-10-08 close
- Market cap$338M as of 2026-08-04 (share count; price 2026-10-08)
- 1-year return+48.8% 2025-10-08 close $2.13 → 2026-10-08 close $3.17
- P/En/a negative earnings
- Gross margin+21.3% FY2013, SEC XBRL
- ROE-66.3% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-02
- Beta0.75 as of 2026-09-02
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How RLMD compares in its sector
- gross marginbottom 10% 189 covered Health Care peers, as of 2026-09-02
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-02
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How RELMADA THERAPEUTICS INC looks technically
RELMADA THERAPEUTICS INC (RLMD) is trading 41.7% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 27 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 42, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 21, in oversold territory (below 30). It just made a new 20-day low, its first since 2025-11-10, breaking below its recent trading range. It is 60.4% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 41.7% below its 200-day average, the long-term trend line — a long-term downtrend | -41.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $4.38 | $4.38 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $5.44 | $5.44 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 27 calendar days ago — the swings before that are what the structure reading is measured on | 27 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 4.65. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 27 trading days ago — a "death cross", a bearish long-term signal | 27 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 42, with sellers in control | 42.2 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 21, in oversold territory (below 30) | 21.4 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($3.10 to $4.27) — its "stochastic" reading is 6 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 6.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 12 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $8.00 | $8.00 |
|---|---|---|
| From the 52-week high | it is 60.4% below its 52-week high (its highest price of the past year) | -60.4% |
| Above the 52-week low | it is 75.8% above its 52-week low (its lowest price of the past year) | +75.8% |
| Below the 52-week high | it is 60.4% below its highest point of the past year | 60.4% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2025-11-10, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day low, its first since 2025-11-10, breaking below its recent trading range | 1 session |
| All-time high | its highest closing price on record is $80.00 (set on 2014-10-29) | $80.00 |
| Given back of the 52-week move | over the past year its closes ranged ($1.93 to $7.86), and it has given back well over two thirds of its rise from last year’s low — 79% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $4.01 to $4.20. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 79.1% |
| From the all-time high | it is 96.0% below its all-time high | -96.0% |
| Nearest price level | it is trading 25.7% below a resistance level at $3.98 — a price it turned at four times since 2024-10-28, most recently on 2026-09-10. Since 2024-10-08 it has 5 such levels below the current price and 10 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +25.7% |
| All-time low | its lowest closing price on record is $0.24 (set on 2025-03-03) | $0.24 |
| Above the all-time low | it is 1220.8% above its all-time low | +1,221% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 96% of the past ~6 months) | 96th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.2114 between its high and its low — about 6.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.2114 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.08 and $4.67 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.08 – $3.87 – $4.67 |
| Typical daily range (% of price) | its price moves about 6.7% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.7% |
| Stretch from the 200-day average | it is trading 10.7 daily ranges below its 200-day average price (41.7% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 10.7 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.54× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.6% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.6% |
|---|---|---|
| Gap filled | a 13.0% gap up opened on 2026-09-11 has been "filled" 14 sessions ago — price traded back through the level the gap left behind, and it took 5 sessions to close | 14 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 6 sessions in a row, a -15.92% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 6 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 26.5 percentage points (the stock lost 25.4% while the market gained 1.0%) | -26.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 54.4 percentage points (the stock lost 50.5% while the market gained 3.8%) | -54.4% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 71.5 percentage points (the stock lost 54.1% while the market gained 17.5%) | -71.5% |
| vs market, 12 months | over the past 12 months this stock beat the market by 33.8 percentage points (the stock gained 48.8% while the market gained 15.0%) | +33.9% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: its RSI momentum gauge is oversold (a beaten-down reading), near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 33% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 30.6% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -33.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 47% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $5.95 — a volume-weighted average of daily closes over 193 sessions, not a true tick-by-tick VWAP. | -46.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 25% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $4.23 — a volume-weighted average of daily closes over 45 sessions, not a true tick-by-tick VWAP. | -25.0% |
Price levels it has turned at before
RLMD last closed at $3.17 on 2026-10-08. Since 2024-10-08 it has turned at 5 prices below its last close and 10 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $3.98 | Resistance | 25.7% above the last close | turned there four times · 2024-10-28 to 2026-09-10 |
| $4.35 | Resistance | 37.2% above the last close | turned there twice · 2026-02-09 to 2026-08-11 |
| $4.54 | Resistance | 43.4% above the last close | turned there twice · 2025-11-28 to 2026-01-23 |
| $0.7375 | Support | 76.7% below the last close | turned there twice · 2025-06-26 to 2025-07-23 |
| $0.69 | Support | 78.2% below the last close | turned there twice · 2025-07-10 to 2025-08-19 |
| $0.3595 | Support | 88.7% below the last close | turned there twice · 2025-01-16 to 2025-02-14 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $4.65.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $3.06 and $3.67 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $4.65.
This reading has stood for 15 trading days, since 2026-09-18.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Recent death cross (50-day crossed below 200-day) · Oversold (14-day RSI below 30) · Pulled back from the 12-month high · Broke down to a new 20-day low · lagging the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$10.75 range $9.00 – $12.00; median $11.00
Analyst estimates, as of 2026-10-05. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["Clinical trial failure or delays, particularly for its lead NDV-01 program.","Reliance on regulatory success for 505(b)(2) approval pathways and IND clearances.","History of losses and potential need for future capital to fund long-term clinical development."]
What changed in the latest 10-Q
AI-assisted comparison of RLMD's 10-Q filed 2026-05-12 against the prior one filed 2025-11-13.
Management's Discussion & Analysis (MD&A)
- Added:
- In newer filing (2026-05-12): Added language specifying NDV-01 Phase 2 trial location as 'in Israel' when describing current trial
- In newer filing (2026-05-12): Added detailed description of NDV-01's controlled-release intravascular delivery technology and mechanism of action (sustained release over 10 days)
- In newer filing (2026-05-12): Added explanation of NDV-01's advantages over conventional administration (single administration in less than 5 minutes vs. three to four hours)
- In newer filing (2026-05-12): Added discussion of how NDV-01 maintains continuous drug exposure to optimize local efficacy while minimizing systemic absorption
- In newer filing (2026-05-12): Added milestone 'NDV-01 Initial 3-Month Data from Phase 3 High-risk, 2nd line BCG-unresponsive NMIBC Trial – Year-end 2026'
- In newer filing (2026-05-12): Changed reference to sepranolone from 'Sepranolone' (capitalized) to 'sepranolone' (lowercase) in Business Overview section
- Removed:
- In older filing (2025-11-13): Removed entire 'Sepranolone Program' section that provided detailed GABAergic system explanation and Phase 2a study data
- In older filing (2025-11-13): Removed milestone 'NDV-01 Twelve-month data from ongoing Phase 2 NMBIC Study – Early 2026'
- Removed language describing 'pausing further work on esmethadone' and replaced with 'terminating further work on esmethadone'
- Reworded:
- Changed 'pausing' to 'terminating' regarding REL-1017 work in Business Overview section (filed 2026-05-12 vs. 2025-11-13)
- Changed milestone language from 'United States Investigative New Drug clearance – 1st Half 2026' to 'United States Investigational New Drug (IND) filing with the U.S. Food and Drug Administration (FDA) to initiate a clinical trial in NMIBC – Mid-2026'
- Changed Phase 3 initiation timeline language from 'in the first-half of 2026' to 'mid-2026' in multiple places
- Changed Sepranolone Phase study language from 'Phase IIb' to 'Phase 2b' and 'Prader-Willi Syndrome' to 'PWS' with revised description
- Changed description of Sepranolone indications from 'Prader-Willi Syndrome, Tourette Syndrome, excessive tremor' to 'PWS, with additional potential indications in TS, essential tremor'
- Changed NDV-01 clinical trial location description from generic 'Phase 2 clinical trial' to 'Phase 2 clinical trial in Israel'
- Expanded 'Our Development Programs' section to lead with NDV-01 instead of Sepranolone
- Notes:
- The older filing appears truncated at the end of the Sepranolone Program section, so complete comparison of that section's removal cannot be fully verified
- Newer filing text also appears truncated at the end of the NDV-01 Program section, limiting full comparison of that program's description
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
4 open-market purchases and 0 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-042 buys ($749150) · 0 sells — 2 buying insiders
- Last 90 days · read to 2026-10-044 buys ($2M) · 0 sells — 2 buying insiders
- Last 180 days · read to 2026-10-044 buys ($2M) · 0 sells — 2 buying insiders
Cluster buying: 4 different insiders reported open-market purchases (SEC code P) of RLMD within a 30-day window between 2025-11-05 and 2025-11-05. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-10. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about RLMD's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding RLMD as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 12,343,620
- Reported value $85,417,852
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about RLMD's institutional holders → See what each manager we track holds →
Short interest (FINRA)
RLMD had 14,463,677 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
RLMD had 13.6% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.25 days to cover at the same settlement.
- Reported short interest (shares) 14,463,677
- Short interest (% of shares outstanding) 13.6%
- Prior settlement (shares) 13,602,542
- Reported change 6.33%
- Days to cover (reported) 9.25
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Ferring Pharmaceuticals (Adstiladrin)
- UroGen Pharma (URGN)
- QED Therapeutics (BridgeBio Pharma) (BBIO)
- AstraZeneca (AZN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare RLMD vs…
Frequently asked questions
What does RELMADA THERAPEUTICS INC (RLMD) do?
Relmada Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies for oncology and central nervous system disorders. The company's lead product candidate is NDV-01, a sustained-release intravesical chemotherapy formulation for non-muscle-invasive bladder cancer (NMIBC). It is also developing sepranolone, a neurosteroid being investigated for conditions such as Prader-Willi syndrome and Tourette syndrome.
What sector is RELMADA THERAPEUTICS INC (RLMD) in?
RELMADA THERAPEUTICS INC (RLMD) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are RELMADA THERAPEUTICS INC's (RLMD) competitors?
Notable peers of RELMADA THERAPEUTICS INC (RLMD) include Ferring Pharmaceuticals (Adstiladrin), UroGen Pharma, QED Therapeutics (BridgeBio Pharma) and AstraZeneca. This peer set is informational only — not financial advice.
Is RELMADA THERAPEUTICS INC (RLMD) overbought or oversold right now?
RELMADA THERAPEUTICS INC (RLMD) is currently in oversold territory (its 14-day RSI is 21, below 30) (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on RLMD come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.